Quick Answer
MBX Biosciences, Inc. reported Research And Development Expense of $79.16 million for the year ending 2025.
- MBX Biosciences, Inc. showed an increase of +37.9% in Research And Development Expense from 2024 to 2025.
- This data is from MBX Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2023: $9.07 million | Q1 2024: $11.05 million | Q2 2024: $14.40 million | Q3 2024: $16.75 million | Q1 2025: $22.41 million | Q2 2025: $17.72 million | Q3 2025: $19.27 million.
- Over the full 3 years of available data (2023 to 2025), MBX Biosciences, Inc.'s Research And Development Expense has grown by 177.4%.
- Historical annual values: Fiscal year 2025: $79.16 million | Fiscal year 2024: $57.42 million | Fiscal year 2023: $28.53 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: